The latest price target for LeMaitre Vascular (NASDAQ:LMAT) was reported by Oppenheimer on November 1, 2024. The analyst firm set a price target for $93.00 expecting LMAT to rise to within 12 months (a possible 0.96% upside). 12 analyst firms have reported ratings in the last year.

The latest analyst rating for LeMaitre Vascular (NASDAQ:LMAT) was provided by Oppenheimer, and LeMaitre Vascular reiterated their outperform rating.

The last upgrade for LeMaitre Vascular Inc happened on April 26, 2024 when Stifel raised their price target to $75. Stifel previously had a hold for LeMaitre Vascular Inc.

The last downgrade for LeMaitre Vascular Inc happened on August 3, 2023 when Jefferies changed their price target from $63 to $67 for LeMaitre Vascular Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of LeMaitre Vascular, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for LeMaitre Vascular was filed on November 1, 2024 so you should expect the next rating to be made available sometime around November 1, 2025.

While ratings are subjective and will change, the latest LeMaitre Vascular (LMAT) rating was a reiterated with a price target of $90.00 to $93.00. The current price LeMaitre Vascular (LMAT) is trading at is $92.12, which is within the analyst’s predicted range.